GSK GSK: viiv cabenuva (cab+rpv La) Superior to daily oral therapy in adolescents with hiv, lata week 96 results - press release
GSK GSK: viiv cabenuva (cab+rpv La) Superior to daily oral therapy in adolescents with hiv, lata week 96 results - press release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.